LXRX
Lexicon Pharmaceuticals, Inc.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.64 | $2.14 | +30% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $1.64 | $2.14 | +30% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $1.64 | $2.14 | +30% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $1.64 | $2.14 | +30% |
| Renaissance Technologies re-entered | Q1 2025(8Q snapshot) | 5Q | $0.74 | $2.14 | +189% |
| AQR Capital Management | Q2 2025(8Q snapshot) | 4Q | $0.53 | $2.14 | +304% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| D.E. Shaw | Q3 2025 | Q4 2025 | → $1.49 | +26% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at LEXICON PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.
- Form 40001062822-26-000108Jun 4, 2026
- Form 40001062822-26-000107Jun 4, 2026
- Form 40001062822-26-000106Jun 4, 2026
- Form 40001062822-26-000105Jun 4, 2026
- Form 40001062822-26-000104Jun 4, 2026
- Form 40001062822-26-000103Jun 4, 2026
- Form 40001062822-26-000102Jun 4, 2026
- Form 40001193125-26-215297May 8, 2026
- Form 40001062822-26-000092May 4, 2026
- Form 40001062822-26-000090May 4, 2026
- Form 40001062822-26-000084May 4, 2026
- Form 40001062822-26-000082May 4, 2026
- Form 40001062822-26-000080May 4, 2026
- Form 40001062822-26-000075May 4, 2026
- Form 40001062822-26-000067May 4, 2026
Fundamentals
XBRL · Lexicon Pharmaceuticals, Inc.Annual figures sourced directly from Lexicon Pharmaceuticals, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for LEXICON PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- 8-KMaterial eventMay 6, 2026
- 8-KMaterial eventApr 30, 2026
- DEF 14AProxy statementMar 16, 2026
- 10-KAnnual reportMar 5, 2026
- 8-KMaterial eventMar 5, 2026
- 8-KMaterial eventFeb 2, 2026
- 8-KMaterial eventJan 29, 2026
- 8-KMaterial eventNov 10, 2025
- 8-KMaterial eventNov 6, 2025
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 10-QQuarterly reportAug 6, 2025
- 8-KMaterial eventAug 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $1.32 | $2.14 | +62% |
| Citadel Advisors | Q4 2025 | open | $1.49 | $2.14 | +44% |
| Renaissance Technologies | Q4 2025 | open | $1.44 | $2.14 | +49% |
| Two Sigma Investments | Q3 2025 | open | $1.18 | $2.14 | +81% |
| D.E. Shaw | Q3 2025 | Q4 2025 | $1.18 | $1.49 | +26% |
| Millennium Management | Q3 2025 | open | $1.18 | $2.14 | +81% |
| AQR Capital Management | Q2 2025 | open | $0.53 | $2.14 | +304% |
| Renaissance Technologies | Q1 2025 | Q2 2025 | $0.74 | $0.53 | -28% |
| Citadel Advisors | Q3 2024 | Q3 2025 | $1.64 | $1.18 | -28% |
| Two Sigma Investments | Q3 2024 | Q1 2025 | $1.64 | $0.78 | -52% |
| Millennium Management | Q3 2024 | Q1 2025 | $1.64 | $0.78 | -52% |
| Point72 Asset Management | Q3 2024 | Q2 2025 | $1.64 | $0.53 | -68% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.